European Commission approves Illumina’s divestment plan for GRAIL
The European Commission, exercising its authority under the EU Merger Regulation (EUMR), has granted approval to Illumina’s proposed divestment of GRAIL. This decision, crucial for the restoration of competitive equilibrium in the blood-based early cancer detection market, follows the Commission’s previous order in October 2023 requiring Illumina to reverse its acquisition of GRAIL. The deal […]